Bionoid Pharma Stock Probability Of Bankruptcy
| BINP Stock | USD 0.11 0.09 45.00% |
Bionoid |
Bionoid Pharma Company probability of distress Analysis
Bionoid Pharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Bionoid Pharma Probability Of Bankruptcy | Over 69% |
Most of Bionoid Pharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bionoid Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Bionoid Pharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Bionoid Pharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Bionoid Pharma financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Bionoid Pharma has a Probability Of Bankruptcy of 69%. This is 59.39% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The probability of bankruptcy for all United States stocks is 73.24% lower than that of the firm.
Bionoid Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bionoid Pharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bionoid Pharma could also be used in its relative valuation, which is a method of valuing Bionoid Pharma by comparing valuation metrics of similar companies.Bionoid Pharma is currently under evaluation in probability of bankruptcy category among its peers.
Bionoid Fundamentals
| Return On Asset | -1.64 | |||
| Operating Margin | (4.22) % | |||
| Current Valuation | 3.81 M | |||
| Shares Outstanding | 42.28 M | |||
| Price To Sales | 540.76 X | |||
| Revenue | 92.26 K | |||
| Gross Profit | 47.48 K | |||
| EBITDA | (385.71 K) | |||
| Net Income | (1.62 M) | |||
| Cash And Equivalents | 127 | |||
| Total Debt | 64.5 K | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (29.92) X | |||
| Cash Flow From Operations | (357.62 K) | |||
| Earnings Per Share | (46.27) X | |||
| Beta | -2.12 | |||
| Market Capitalization | 42.28 M |
About Bionoid Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bionoid Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionoid Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionoid Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bionoid Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionoid Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionoid Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Bionoid Pink Sheet
The ability to find closely correlated positions to Bionoid Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionoid Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionoid Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionoid Pharma to buy it.
The correlation of Bionoid Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionoid Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionoid Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionoid Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Bionoid Pink Sheet Analysis
When running Bionoid Pharma's price analysis, check to measure Bionoid Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionoid Pharma is operating at the current time. Most of Bionoid Pharma's value examination focuses on studying past and present price action to predict the probability of Bionoid Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionoid Pharma's price. Additionally, you may evaluate how the addition of Bionoid Pharma to your portfolios can decrease your overall portfolio volatility.